| 000 | 01264nam a2200325Ia 4500 | ||
|---|---|---|---|
| 001 | 009305 | ||
| 008 | 141222s9999 xx 000 0 und d | ||
| 040 | _aDB/INS | ||
| 041 | 0 | _aspa | |
| 222 | 0 | _aBiomédica | |
| 245 | 0 | 0 | _aTuberculosis in patientes treated with tumor necrosis factor-alpha antagonists living in an endemic area. Is the risk worthwhile? |
| 245 | 0 | 0 | _cAdriana Rojas-Villarraga, Carlos Andrés Agudelo, Ricardo Pineda-Tamayo … [et.al] |
| 260 | _aBogotá, D. C | ||
| 260 | _bInstituto Nacional de Salud | ||
| 260 | _c2007 | ||
| 300 | _a159-71 | ||
| 300 | _bilus.;tbls | ||
| 362 | 1 | _aVol. 27, no. 2 (jun. 2007) | |
| 520 | _aTumor necrosis factor alpha antagonists (TNFA) are biological agents to treat chronic inflammatory and autoimmune diseases. However, their use is associated with an increased rate of tuberculosis, endemic mycoses, and intracellular bacterial infections. S | ||
| 650 | 1 | _aTuberculosis | |
| 650 | 2 | _aEnfermedades endémicas | |
| 650 | 2 | _aFactor de necrosis tumoral alfa | |
| 651 | _aColombia | ||
| 700 | 1 | _aAgudelo, Carlos Andrés | |
| 700 | 1 | _aAnaya, Juan Manuel | |
| 700 | 1 | _aMatute, Gustavo | |
| 700 | 1 | _aPineda-Tamayo, Ricardo | |
| 700 | 1 | _aPorras, Alvaro | |
| 700 | 1 | _aRojas-Villarraga, Adriana | |
| 999 |
_c18724 _d18724 |
||